Literature DB >> 25412721

[Therapy of hypertrophic scars and keloids].

R Aschoff1.   

Abstract

Keloids mostly occur between the ages of 10 and 30 years and grow continuously beyond the original margins of the scar. Beside the cosmetic impairment they often lead to pruritus, pain, contractures and decrease in quality of life. Advances in the understanding of the genetics and pathogenesis of hypertrophic scars and keloids have led to new therapeutic options. Nevertheless treatment remains a challenge and there is no single treatment modality which is appropriate for all types of scars. Combined approaches are becoming more widely employed as they are more effective than single treatment modalities. This article gives an overview of hypertrophic scars and keloids, their pathogenesis and recommended therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412721     DOI: 10.1007/s00105-014-3546-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  36 in total

1.  Cryotherapy modifies synthetic activity and differentiation of keloidal fibroblasts in vitro.

Authors:  A Dalkowski; S Fimmel; C Beutler; Ch C Zouboulis
Journal:  Exp Dermatol       Date:  2003-10       Impact factor: 3.960

Review 2.  International clinical recommendations on scar management.

Authors:  Thomas A Mustoe; Rodney D Cooter; Michael H Gold; F D Richard Hobbs; Albert-Adrien Ramelet; Peter G Shakespeare; Maurizio Stella; Luc Téot; Fiona M Wood; Ulrich E Ziegler
Journal:  Plast Reconstr Surg       Date:  2002-08       Impact factor: 4.730

3.  Intralesional cryosurgery for the treatment of hypertrophic scars and keloids.

Authors:  Yaron Har-Shai; Wilfred Brown; Norbert Pallua; Christos C Zouboulis
Journal:  Plast Reconstr Surg       Date:  2010-11       Impact factor: 4.730

4.  Dose-response relationship and dose optimization in radiotherapy of postoperative keloids.

Authors:  Takashi Sakamoto; Natsuo Oya; Keiko Shibuya; Yasushi Nagata; Masahiro Hiraoka
Journal:  Radiother Oncol       Date:  2009-02-07       Impact factor: 6.280

Review 5.  Keloid scarring: bench and bedside.

Authors:  Oliver Seifert; Ulrich Mrowietz
Journal:  Arch Dermatol Res       Date:  2009-04-10       Impact factor: 3.017

6.  p53 and apoptosis alterations in keloids and keloid fibroblasts.

Authors:  D A Ladin; Z Hou; D Patel; M McPhail; J C Olson; G M Saed; D P Fivenson
Journal:  Wound Repair Regen       Date:  1998 Jan-Feb       Impact factor: 3.617

Review 7.  Is radiation therapy for keloids acceptable? The risk of radiation-induced carcinogenesis.

Authors:  Rei Ogawa; Sumiko Yoshitatsu; Ken Yoshida; Tsuguhiro Miyashita
Journal:  Plast Reconstr Surg       Date:  2009-10       Impact factor: 4.730

Review 8.  Laser and light-based treatment of Keloids--a review.

Authors:  A D Mamalis; H Lev-Tov; D-H Nguyen; J R Jagdeo
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-08-27       Impact factor: 6.166

Review 9.  The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis.

Authors:  Alexander Anzarut; Jarret Olson; Prabhjyot Singh; Brian H Rowe; Edward E Tredget
Journal:  J Plast Reconstr Aesthet Surg       Date:  2008-01-14       Impact factor: 2.740

10.  Effect of carbon dioxide laser ablation followed by intralesional steroids on keloids.

Authors:  Gaurav A Garg; Prajct P Sao; Uday S Khopkar
Journal:  J Cutan Aesthet Surg       Date:  2011-01
View more
  2 in total

1.  Increased calcium channel in the lamina propria of aging rat.

Authors:  Ji Min Kim; Hyoung-Sam Heo; Sung-Chan Shin; Hyun-Keun Kwon; Jin-Choon Lee; Eui-Suk Sung; Hyung-Sik Kim; Gi Cheol Park; Byung-Joo Lee
Journal:  Aging (Albany NY)       Date:  2019-10-31       Impact factor: 5.682

2.  Loureirin A Exerts Antikeloid Activity by Antagonizing the TGF-β1/Smad Signalling Pathway.

Authors:  Hui Ma; Xingwu Duan; Runtian Zhang; Hang Li; Yang Guo; Ye Tian; Min Huang; Guangshan Chen; Zi Wang; Lingling Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-15       Impact factor: 2.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.